Antitumor activity of recombinant adenoviral vectors expressing murine IFN-α in mice injected with metastatic IFN-resistant tumor cells

Laura Santodonato, Maria Ferrantini, Fabio Palombo, Luigi Aurisicchio, Paola Delmastro, Nicola La Monica, Stefania Di Marco, Gennaro Ciliberto, Mark X. Du, Milton W. Taylor, Filippo Belardelli

Research output: Contribution to journalArticle

Abstract

Recent studies have shown that gene therapy with type I interferon (IFN) in an adenovirus vector is a powerful tool to suppress the growth of human tumors transplanted in immune-deficient mice. However, in these studies the host immune-mediated effects, which may be important in mediating the long-term control of tumor growth by these cytokines, was not studied. In this paper, we evaluate the antitumor efficacy of different adenoviral vectors containing mouse IFN-α genes (i.e., a first-generation replication-defective vector containing IFN-α1 and two different second-generation vectors containing IFN-α2) in immunocompetent DBA/2 mice transplanted with highly metastatic Friend leukemic cells resistant in vitro to type I IFN. We found that injection of all the different adenovirus vectors containing mouse IFN-α genes resulted in a marked antitumor response in mice transplanted either subcutaneously or intravenously with IFN-resistant Friend leukemic cells compared to tumor-bearing animals inoculated with a control vector. Tumor growth inhibition after injection of IFN-adenovirus vectors was associated with a prolonged presence of high IFN levels in the sera of the injected mice. Suppression of metastatic tumor growth was also observed after a single injection of the IFN-adenovirus recombinant vectors, whereas a comparable antitumor response generally required several injections of high doses of IFN. Altogether, these results demonstrate that IFN-adenoviral vectors can efficiently inhibit metastatic tumor growth by host-mediated mechanisms and suggest that adenovirus-mediated IFN-α gene therapy may represent an attractive alternative to the conventional clinical use of this cytokine, which generally requires multiple injections of high IFN doses for a prolonged period of time.

Original languageEnglish
Pages (from-to)63-72
Number of pages10
JournalCancer Gene Therapy
Volume8
Issue number1
Publication statusPublished - 2001

Fingerprint

Interferons
Neoplasms
Adenoviridae
Injections
Growth
Interferon Type I
Genetic Therapy
Cytokines
Inbred DBA Mouse
Genes

Keywords

  • Adenoviral vectors
  • Gene therapy
  • IFN-α
  • Mice
  • Tumor

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Santodonato, L., Ferrantini, M., Palombo, F., Aurisicchio, L., Delmastro, P., La Monica, N., ... Belardelli, F. (2001). Antitumor activity of recombinant adenoviral vectors expressing murine IFN-α in mice injected with metastatic IFN-resistant tumor cells. Cancer Gene Therapy, 8(1), 63-72.

Antitumor activity of recombinant adenoviral vectors expressing murine IFN-α in mice injected with metastatic IFN-resistant tumor cells. / Santodonato, Laura; Ferrantini, Maria; Palombo, Fabio; Aurisicchio, Luigi; Delmastro, Paola; La Monica, Nicola; Di Marco, Stefania; Ciliberto, Gennaro; Du, Mark X.; Taylor, Milton W.; Belardelli, Filippo.

In: Cancer Gene Therapy, Vol. 8, No. 1, 2001, p. 63-72.

Research output: Contribution to journalArticle

Santodonato, L, Ferrantini, M, Palombo, F, Aurisicchio, L, Delmastro, P, La Monica, N, Di Marco, S, Ciliberto, G, Du, MX, Taylor, MW & Belardelli, F 2001, 'Antitumor activity of recombinant adenoviral vectors expressing murine IFN-α in mice injected with metastatic IFN-resistant tumor cells', Cancer Gene Therapy, vol. 8, no. 1, pp. 63-72.
Santodonato L, Ferrantini M, Palombo F, Aurisicchio L, Delmastro P, La Monica N et al. Antitumor activity of recombinant adenoviral vectors expressing murine IFN-α in mice injected with metastatic IFN-resistant tumor cells. Cancer Gene Therapy. 2001;8(1):63-72.
Santodonato, Laura ; Ferrantini, Maria ; Palombo, Fabio ; Aurisicchio, Luigi ; Delmastro, Paola ; La Monica, Nicola ; Di Marco, Stefania ; Ciliberto, Gennaro ; Du, Mark X. ; Taylor, Milton W. ; Belardelli, Filippo. / Antitumor activity of recombinant adenoviral vectors expressing murine IFN-α in mice injected with metastatic IFN-resistant tumor cells. In: Cancer Gene Therapy. 2001 ; Vol. 8, No. 1. pp. 63-72.
@article{0af10a712fe04350a696d1729cf42769,
title = "Antitumor activity of recombinant adenoviral vectors expressing murine IFN-α in mice injected with metastatic IFN-resistant tumor cells",
abstract = "Recent studies have shown that gene therapy with type I interferon (IFN) in an adenovirus vector is a powerful tool to suppress the growth of human tumors transplanted in immune-deficient mice. However, in these studies the host immune-mediated effects, which may be important in mediating the long-term control of tumor growth by these cytokines, was not studied. In this paper, we evaluate the antitumor efficacy of different adenoviral vectors containing mouse IFN-α genes (i.e., a first-generation replication-defective vector containing IFN-α1 and two different second-generation vectors containing IFN-α2) in immunocompetent DBA/2 mice transplanted with highly metastatic Friend leukemic cells resistant in vitro to type I IFN. We found that injection of all the different adenovirus vectors containing mouse IFN-α genes resulted in a marked antitumor response in mice transplanted either subcutaneously or intravenously with IFN-resistant Friend leukemic cells compared to tumor-bearing animals inoculated with a control vector. Tumor growth inhibition after injection of IFN-adenovirus vectors was associated with a prolonged presence of high IFN levels in the sera of the injected mice. Suppression of metastatic tumor growth was also observed after a single injection of the IFN-adenovirus recombinant vectors, whereas a comparable antitumor response generally required several injections of high doses of IFN. Altogether, these results demonstrate that IFN-adenoviral vectors can efficiently inhibit metastatic tumor growth by host-mediated mechanisms and suggest that adenovirus-mediated IFN-α gene therapy may represent an attractive alternative to the conventional clinical use of this cytokine, which generally requires multiple injections of high IFN doses for a prolonged period of time.",
keywords = "Adenoviral vectors, Gene therapy, IFN-α, Mice, Tumor",
author = "Laura Santodonato and Maria Ferrantini and Fabio Palombo and Luigi Aurisicchio and Paola Delmastro and {La Monica}, Nicola and {Di Marco}, Stefania and Gennaro Ciliberto and Du, {Mark X.} and Taylor, {Milton W.} and Filippo Belardelli",
year = "2001",
language = "English",
volume = "8",
pages = "63--72",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Antitumor activity of recombinant adenoviral vectors expressing murine IFN-α in mice injected with metastatic IFN-resistant tumor cells

AU - Santodonato, Laura

AU - Ferrantini, Maria

AU - Palombo, Fabio

AU - Aurisicchio, Luigi

AU - Delmastro, Paola

AU - La Monica, Nicola

AU - Di Marco, Stefania

AU - Ciliberto, Gennaro

AU - Du, Mark X.

AU - Taylor, Milton W.

AU - Belardelli, Filippo

PY - 2001

Y1 - 2001

N2 - Recent studies have shown that gene therapy with type I interferon (IFN) in an adenovirus vector is a powerful tool to suppress the growth of human tumors transplanted in immune-deficient mice. However, in these studies the host immune-mediated effects, which may be important in mediating the long-term control of tumor growth by these cytokines, was not studied. In this paper, we evaluate the antitumor efficacy of different adenoviral vectors containing mouse IFN-α genes (i.e., a first-generation replication-defective vector containing IFN-α1 and two different second-generation vectors containing IFN-α2) in immunocompetent DBA/2 mice transplanted with highly metastatic Friend leukemic cells resistant in vitro to type I IFN. We found that injection of all the different adenovirus vectors containing mouse IFN-α genes resulted in a marked antitumor response in mice transplanted either subcutaneously or intravenously with IFN-resistant Friend leukemic cells compared to tumor-bearing animals inoculated with a control vector. Tumor growth inhibition after injection of IFN-adenovirus vectors was associated with a prolonged presence of high IFN levels in the sera of the injected mice. Suppression of metastatic tumor growth was also observed after a single injection of the IFN-adenovirus recombinant vectors, whereas a comparable antitumor response generally required several injections of high doses of IFN. Altogether, these results demonstrate that IFN-adenoviral vectors can efficiently inhibit metastatic tumor growth by host-mediated mechanisms and suggest that adenovirus-mediated IFN-α gene therapy may represent an attractive alternative to the conventional clinical use of this cytokine, which generally requires multiple injections of high IFN doses for a prolonged period of time.

AB - Recent studies have shown that gene therapy with type I interferon (IFN) in an adenovirus vector is a powerful tool to suppress the growth of human tumors transplanted in immune-deficient mice. However, in these studies the host immune-mediated effects, which may be important in mediating the long-term control of tumor growth by these cytokines, was not studied. In this paper, we evaluate the antitumor efficacy of different adenoviral vectors containing mouse IFN-α genes (i.e., a first-generation replication-defective vector containing IFN-α1 and two different second-generation vectors containing IFN-α2) in immunocompetent DBA/2 mice transplanted with highly metastatic Friend leukemic cells resistant in vitro to type I IFN. We found that injection of all the different adenovirus vectors containing mouse IFN-α genes resulted in a marked antitumor response in mice transplanted either subcutaneously or intravenously with IFN-resistant Friend leukemic cells compared to tumor-bearing animals inoculated with a control vector. Tumor growth inhibition after injection of IFN-adenovirus vectors was associated with a prolonged presence of high IFN levels in the sera of the injected mice. Suppression of metastatic tumor growth was also observed after a single injection of the IFN-adenovirus recombinant vectors, whereas a comparable antitumor response generally required several injections of high doses of IFN. Altogether, these results demonstrate that IFN-adenoviral vectors can efficiently inhibit metastatic tumor growth by host-mediated mechanisms and suggest that adenovirus-mediated IFN-α gene therapy may represent an attractive alternative to the conventional clinical use of this cytokine, which generally requires multiple injections of high IFN doses for a prolonged period of time.

KW - Adenoviral vectors

KW - Gene therapy

KW - IFN-α

KW - Mice

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=0035125085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035125085&partnerID=8YFLogxK

M3 - Article

C2 - 11219495

AN - SCOPUS:0035125085

VL - 8

SP - 63

EP - 72

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 1

ER -